Skip to main content
. 2023 Mar 2;14:1142087. doi: 10.3389/fphar.2023.1142087

FIGURE 2.

FIGURE 2

Recommendations for HER2-positive MBC (Giordano et al., 2022). After the failure of multiple lines of treatment, there is insufficient evidence to recommend one regimen over another due to the lack of head-to-head trials. HER2, Human epidermal growth factor receptor 2. T-DM1, trastuzumab emtansine. T-Dxd, trastuzumab deruxtecan.